From Rare to Common Disorders:
Maximise on the Opportunity in CNS Gene Therapies
Returning digitally in 2021, the 2nd Annual Gene Therapy for Neurological Disorders Europe meeting will possibly be your last chance to attend a European meeting without the airmiles!
Focusing on the industry’s challenges of developing and delivering gene therapies to the CNS and bringing fresh faces and emerging companies into the conversation, this is not one to miss as you seek to accelerate the development of your neurological gene therapy.
Discover the latest neurological targets, familiarise yourself with the European landscape, and debate and discuss with the leading minds of the field from the likes of UCB, Lysogene, UniQure and AskBio, as they seek to harness the opportunity and move from rare to common disorders such as Alzheimer’s, Parkinson’s and epilepsy.
See the full event guide now to learn more about the world class speaker faculty and topics scheduled for July.
Attendees of Gene Therapy for Neurological Disorders 2020 said:
Shephard Mpofu, Senior Vice President & Chief Medical Officer, Novartis Gene Therapies
Michael Fossel, President, Telocyte
"A great opportunity for learning from other industry experts.”
Marie-Laure Nevoret, Senior Lead - Clinical Development, REGENXBIO
What Will You Learn?
The latest clinical updates from the most advanced companies to inform your future strategies
The novel neurological targets being pursued by gene therapy developers to learn of the latest CNS opportunities
How to optimize the use of preclinical models and biomarkers for improved translation and reduced risk to patients
The specific regulatory challenges of designing trials for both rare and common disorders from the European Medicines Agency
The advantages and disadvantages of established and novel routes of administration for CNS gene therapy delivery
The thoughts of the neurosurgeons at the forefront of neurosurgical delivery and their thoughts on the technical challenges facing different programs
Measuring and overcoming CNS immunogenic responses